Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer

In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including:Transitioning from second- to third-line therapyFactors in selecting among available therapiesKey predictors of improved outcomes with regorafenib vs TAS-102Presenters:Chiara Cremolini, MD, PhDMedical Oncologist  Unit of Medical Oncology 2  Azienda Ospedaliero-Universitaria PisanaProfessorDepartment of Translational Research and New Technologies in Medicine and SurgeryUniversity of PisaPisa, Italy Teresa Macarulla, MD, PhDMedical OncologistHead, Gastrointestinal and Endocrine Tumors Unit  Division of Medical OncologyVall d´Hebrón Institute of OncologyBarcelona, SpainContent based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Follow along with the slideset:https://bit.ly/3FjekMoLink to full program:https://bit.ly/33yrIyh

There are no comments yet.

Please log in to write the first comment.